Unigestion Holding SA grew its position in shares of Merck & Co., Inc. (NYSE:MRK) by 8.5% during the third quarter, Holdings Channel reports. The firm owned 162,591 shares of the company’s stock after acquiring an additional 12,679 shares during the quarter. Unigestion Holding SA’s holdings in Merck & Co., Inc. were worth $13,686,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Bath Savings Trust Co raised its stake in shares of Merck & Co., Inc. by 67.8% in the second quarter. Bath Savings Trust Co now owns 6,799 shares of the company’s stock valued at $570,000 after acquiring an additional 2,746 shares in the last quarter. Pensionfund DSM Netherlands purchased a new position in shares of Merck & Co., Inc. during the second quarter worth about $5,953,000. Pensionfund Sabic purchased a new position in shares of Merck & Co., Inc. during the second quarter worth about $3,941,000. South Texas Money Management Ltd. grew its holdings in shares of Merck & Co., Inc. by 0.5% during the second quarter. South Texas Money Management Ltd. now owns 645,800 shares of the company’s stock worth $54,150,000 after purchasing an additional 2,952 shares during the last quarter. Finally, Stillwater Investment Management LLC grew its holdings in shares of Merck & Co., Inc. by 2.6% during the second quarter. Stillwater Investment Management LLC now owns 4,796 shares of the company’s stock worth $402,000 after purchasing an additional 120 shares during the last quarter. Institutional investors own 74.95% of the company’s stock.
Shares of NYSE MRK traded up $0.71 during midday trading on Friday, reaching $83.59. 6,348,084 shares of the company were exchanged, compared to its average volume of 10,105,755. The company has a current ratio of 1.21, a quick ratio of 0.92 and a debt-to-equity ratio of 0.82. Merck & Co., Inc. has a 1 year low of $70.89 and a 1 year high of $87.35. The stock has a fifty day simple moving average of $84.03 and a 200 day simple moving average of $82.71. The stock has a market cap of $212.31 billion, a P/E ratio of 19.26, a PEG ratio of 1.80 and a beta of 0.54.
Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, October 29th. The company reported $1.51 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.24 by $0.27. Merck & Co., Inc. had a return on equity of 47.94% and a net margin of 20.26%. The firm had revenue of $12.40 billion for the quarter, compared to analyst estimates of $11.59 billion. During the same quarter last year, the company posted $1.19 earnings per share. The business’s revenue was up 14.9% on a year-over-year basis. As a group, analysts forecast that Merck & Co., Inc. will post 5.16 earnings per share for the current year.
Several equities analysts have issued reports on the company. Svb Leerink assumed coverage on Merck & Co., Inc. in a report on Friday, August 16th. They set an “outperform” rating and a $103.00 price objective on the stock. JPMorgan Chase & Co. set a $96.00 price objective on Merck & Co., Inc. and gave the stock a “buy” rating in a report on Thursday, October 10th. Mizuho raised their price objective on Merck & Co., Inc. from $97.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. ValuEngine lowered Merck & Co., Inc. from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. Finally, Argus raised their price objective on Merck & Co., Inc. to $105.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $95.13.
Merck & Co., Inc. Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Further Reading: How much can an individual set aside as a catch-up contribution?
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.